Free Trial
NASDAQ:PHVS

Pharvaris Q3 2023 Earnings Report

Pharvaris logo
$23.12 -0.23 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$23.18 +0.05 (+0.24%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 2, 2023
Conference Call Time
8:00AM ET

Earnings Documents

Pharvaris Earnings Headlines

Pharvaris (NASDAQ:PHVS) Upgraded at Zacks Research
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Q3 Earnings Estimate for Pharvaris Issued By Leerink Partnrs
Cantor Fitzgerald Lifts Earnings Estimates for Pharvaris
Wedbush Issues Positive Estimate for Pharvaris Earnings
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

View Pharvaris Profile

More Earnings Resources from MarketBeat